NewsBenzingaBTIG réitère son achat sur Cullinan Therapeutics, maintient un objectif de prix de 40$. BTIG réitère son achat sur Cullinan Therapeutics, maintient un objectif de prix de 40$. Benzinga 2026.09.25 09:49 (GMT+0) Open on Benzinga Other news Freshworks Stock Has Strong Momentum at New 52-Week Highs, But There’s 1 Reason for Caution Why Is Snowflake Stock Surging Monday? 18 Globo Titles Heading To Netflix In Unprecedented Licensing Agreement ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment RBC Capital Maintains Outperform on Regions Financial, Lowers Price Target to $32 Wells Fargo Maintains Equal-Weight on Greif, Lowers Price Target to $88
